Status:
COMPLETED
Safety Surveillance of VaxigripTetra® and Efluelda® Influenza Vaccines in Europe During the Influenza Season 2023/24
Lead Sponsor:
Sanofi
Conditions:
Influenza Immunization (Healthy Volunteers)
Eligibility:
All Genders
6+ years
Brief Summary
This EPSS will determine the vaccinee reporting rates (RRs) of suspected ADRs following routine vaccination with VaxigripTetra® and Efluelda® respectively, during the NH influenza season 2023/24. The ...
Eligibility Criteria
Inclusion
- There are no formal inclusion criteria. Individuals who approach the site for vaccination and agree to receive a vaccination card will be included and vaccinated with the respective vaccine brand according to the country of their location, recommendations for the individual vaccines as well as national recommendations
Exclusion
- \-
Key Trial Info
Start Date :
October 2 2023
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 15 2023
Estimated Enrollment :
2078 Patients enrolled
Trial Details
Trial ID
NCT06059456
Start Date
October 2 2023
End Date
December 15 2023
Last Update
March 24 2025
Active Locations (11)
Enter a location and click search to find clinical trials sorted by distance.
1
Investigational Site Number : 2460001
Helsinki, Finland, 00290
2
Investigational Site Number : 2760001
Martinsried, Germany, 82152
3
Investigational Site Number : 2760002
Martinsried, Germany, 82152
4
Investigational Site Number : 2760003
Martinsried, Germany, 82152